elderly, service educational activities, and public airports to apply for donation of Federal surplus personal property. The SF 123 serves as the transfer instrument and includes item descriptions, transportation instructions, nondiscrimination assurances, and approval signatures.

**B. Annual Reporting Burden**

*Respondents:* 63,000.
*Responses Per Respondent:* 1.
*Hours Per Response:* 0.3.
*Total Burden Hours:* 18,900.
*Obtaining Copies of Proposals:*

Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat (VIR), 1800 F Street, NW., Room 4035, Washington, DC 20405, telephone (202) 208–7312. Please cite OMB Control No. 3090–0014, Standard Form (SF) 123, Transfer Order-Surplus Personal Property and Continuation Sheet, in all correspondence.

Dated: February 2, 2006.

**Michael W. Carleton,**

*Chief Information Officer.*

[FR Doc. E6–2024 Filed 2–13–06; 8:45 am]

**BILLING CODE 6820–YT–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### National Institute for Occupational Safety and Health; National Occupational Research Agenda

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following public meeting and request for information:

*Name:* Opportunity to Provide Input for the National Occupational Research Agenda (NORA).

*Time and Date:* March 13, 2006, 9 a.m.–5 p.m. EST.

*Place:* Department of Health and Human Services, Great Hall, The Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

*Status:* This meeting is open to the public, limited only by the space available.

*Background:* NORA is a framework to guide occupational safety and health research for the nation. NORA seeks to focus research in order to reduce work-related injury and illness. As the program approaches a ten-year milestone, NIOSH is accepting input from individuals and organizations on important research issues and agendas. This input will assist in the development of the initiative's future direction, which will be based on eight different industry sector groups.

The public meetings are open to everyone, including all workers, professional societies, organized labor, employers, researchers, health professionals, government officials, and elected officials. Broad participation is desired. All participants are requested to register for the free meeting at the NORA Web page or onsite the day of the meeting. Participants wishing to speak are encouraged to register early.

*Purpose:* The meeting will address priorities for research during a morning and an afternoon public comment period. Stakeholders will be invited to speak for 5 minutes on an important occupational safety and health issue, including those that occur in multiple sectors. Participants may register to speak during either the morning or the afternoon session, though they are encouraged to stay for both sessions should they choose.

Types of occupational safety and health issues might include diseases, injuries, exposures, populations at risk, and needs of occupational safety and health systems. Falls from heights, for example, might be a top injury issue for the residential construction industry. Low back pain and related back disorders might be a top disease concern for the urban transit industry.

If possible, please include as much information as might be useful for understanding the safety or health research priority you identify. Such information could include characterization of the frequency and severity with which the injury, illness, or hazardous exposure is occurring and of the factors you believe might be causing the health or safety issue. Input is also requested on the types of research that you believe might make a difference and which partners (e.g., specific industry associations, labor organizations, research organizations, governmental agencies) should be involved in informing research efforts and solutions.

All presentations will be entered into the NORA Docket, which is maintained by NIOSH. All comments in the NORA Docket will be used to help shape sector-specific and related cross-sector research agendas for the nation. Comments may also be e-mailed to *niocindocket@cdc.gov* or sent via postal mail to Docket NIOSH–047, Robert A. Taft Laboratories (C–34), 4676 Columbia Parkway, Cincinnati, Ohio 45226. More information about NORA can be found on the NORA Web page at *http://www.cdc.gov/niosh/nora/townhall.*

*For Further Information Contact:* Sid Soderholm, PhD, NORA Coordinator, (202) 401–0721.

Stakeholders are also invited to submit comments electronically at the NORA Web page *http://www.cdc.gov/niosh/nora.* Comments submitted to the Web page by others can also be viewed there along with information about similar meetings that were held earlier.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: February 6, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6–2017 Filed 2–13–06; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2006N–0065]**

### Emerging Clostridial Disease; Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA), on behalf of the Centers for Disease Control and Prevention (CDC) and the National Institute of Allergy and Infectious Diseases (NIAID) are announcing a public workshop entitled ''Emerging Clostridial Disease.'' This public workshop is intended to develop a draft research agenda to better understand the virulence, pathogenesis, host factors, and nonantimicrobial risk factors contributing to reports of morbidity and mortality associated with *Clostridium sordellii* (*C. sordellii*) and *Clostridium difficile* (*C. difficile*). Additionally, our goals are to identify research needs and priorities that will enable rapid progress as well as to develop and provide recommendations for detecting cases and conducting surveillance of diseases and organisms.

**DATES**: The public workshop will be held on May 11, 2006, from 8:30 a.m. to 4:30 p.m. See section III of this document for information on how to

register to attend or present at the workshop. You must register by close of business on April 15, 2006, to attend or participate.

We are opening a docket to receive your written or electronic comments (see **ADDRESSES**). Written or electronic comments must be submitted to the docket by June 15, 2006.

**ADDRESSES:** The public workshop will be held at the Centers for Disease Control and Prevention, 1600 Clifton Rd., NE., CDC Roybal Campus, Bldg. 19, Auditorium A, Atlanta, GA 30333.

Submit written comments to Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments*.

**FOR FURTHER INFORMATION CONTACT:** Workshop Coordinator, Center for Drug Evaluation and Research (HFD–006), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–6779, FAX: 301–827–4312, e-mail: *cderexsec@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:**

## I. Why Are We Holding a Public Workshop?

This workshop has been developed in response to reports of morbidity and mortality associated with *C. sordellii* and *C. difficile*. These reports include cases and clusters of *C. sordellii* toxic shock syndrome following treatment with mifepristone, *C. sordellii* sepsis associated with tissue grafts, and rapidly fatal toxin-mediated cases of community-associated *C. difficile* infection. The primary goal of the workshop is to bring together scientific and public health experts to develop a draft research agenda. This research agenda is expected to lead to better understanding of the virulence, pathogenesis, host factors, and nonantimicrobial risk factors contributing to these reports and to identify research needs and priorities in these areas. As part of a research agenda, the workshop will assist in the development of recommendations for detecting cases and conducting surveillance. The meeting focus will be on increasing our understanding of severe community associated *C. difficile* and *C. sordellii* disease and of disease in otherwise healthy populations previously thought to be at low risk.

## II. What Are the Issues We Intend to Address at the Workshop?

1. What clinical and laboratory surveillance data are needed to help guide infection prevention?

2. Are there characteristics of the clinical presentations of these infections that suggest measures that could prevent or mitigate them?

3. How does our current understanding of the pathophysiology and risk factors associated with these infections inform future research and public health actions?

4. What are the gaps in basic research that are critical to a better understanding of the pathogenesis of *C. sordellii* and *C. difficile?*

## III. How Do You Register?

Registration is required to attend or participate in the workshop. Your registration must be received by the close of business on April 15, 2006. Registration is free. Seats are limited, so please register as soon as possible. Space will be filled in order of receipt of registration. Those registered will receive confirmation on April 18, 2006. Registration will close after available space fills. You will not be notified if registration has closed before your registration is received. There will be no on-site registration the day of the workshop.

Time will be allowed during the scheduled agenda for attendees to ask questions of panelists, to participate in the discussion, and to provide input to the sponsoring agencies on future research, surveillance, and case detection. In addition, we strongly encourage written submissions to the docket.

If you need special accommodations due to disability, please contact the Workshop Coordinator (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance of the workshop.

*Registration Form Instructions*: To register to attend the workshop, complete the following registration form and submit via:

- E-mail: *cderexsec@cder.fda.gov*;
- FAX: 301–827–4312; or
- Mail to: Food and Drug Administration, Center for Drug Evaluation and Research, Office of Executive Programs, Executive Operations Staff (HFD–006), 5600 Fishers Lane, Rockville, MD 20857, Attn: Workshop Coordinator.

Name: _____
Company Name: _____
Mailing Address: _____
City: _____ State: _____
Zip Code: _____
Phone: ( ) _____
Fax: ( ) _____
E-mail: ( ) _____
U.S. Citizen Yes/No (Required by CDC Security)

## IV. How Should You Send Comments on the Issues?

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments should be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. To ensure consideration of your comments, we must receive any written or electronic comments by the date indicated (see **DATES**).

## V. Will Meeting Transcripts Be Available?

You can examine a transcript of the May 11, 2006, public workshop on the Internet at *http://frwebgate.access.gpo.gov/cgi-bin/leaving.cq* approximately 30 days after the workshop or at the Division of Dockets Management (see **ADDRESSES**), Monday through Friday between 9 a.m. and 4 p.m. You may also request a copy of the transcript from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the public workshop at a cost of 10 cents per page.

Dated: February 9, 2006.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 06–1371 Filed 2–10–06; 11:33 am]

**BILLING CODE 4160–01–S**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2000D–1400]**

### Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a document entitled ''Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications,'' dated February 2006. The guidance is intended to provide sponsors with recommendations for the conduct of developmental toxicity studies for